• Tolerabiltiy of Oral Paclitaxel in Cancer-Bearing Dogs

    Currently Enrolling

    Research Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second

    Study Details
  • Canine Mast Cell Tumor Study

    Currently Enrolling

    This study will evaluate whether or not a small biopsy from a mast cell tumor is accurate for prognostication purposes.

    Study Details
  • Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH)

    Currently Enrolling

    Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

    Study Details
  • Sorafenib for the Treatment of Solid Tumors in Dogs

    No Longer Enrolling

    We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

    Study Details
  • Rapamycin for the Treatment of Hemangiosarcoma in Dogs

    No Longer Enrolling

    Based on its reported tolerability in dogs (alone and in combination with chemotherapy) this study will ask whether Rapamycin may improve treatment outcomes for dogs with hemangiosarcoma, and more precisely, to understand the hemangiosarcoma genotypes which may most benefit from its use.

    Study Details